TITLE

Circulating Tumor Cell Testing

AUTHOR(S)
Xue, Chengsen; Hill, Carla G.; Mc Closkey, Thomas W.
PUB. DATE
March 2013
SOURCE
Applied Clinical Trials;Mar2013, Vol. 22 Issue 3, p32
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the benefits and limitations on a circulating tumor cell (CTC) test that are required to fulfill an unmet need in oncology clinical trials and disease management practices. It informs about CellSearch System by Veridex LLC which is designed to enrich and enumerate CTCs in metastatic cancers. It mentions that CTC test is an antibody-independent system and causes minimal cell losses with high recovery and high purity.
ACCESSION #
86412477

 

Related Articles

  • PRODUCTS & SERVICES.  // Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p44 

    This section offers news briefs related to the fields of hematology and oncology. A study is being conducted by researchers at the Herbert Irving Comprehensive Cancer Center of New York-Presbyterian Hospital and Columbia University Medical Center on paclitaxel protein-bound as an alternative to...

  • Increasing frequency of reirradiation studies in radiation oncology: systematic review of highly cited articles. Nieder, Carsten; Andratschke, Nicolaus H.; Grosu, Anca L. // American Journal of Cancer Research;2013, Vol. 3 Issue 2, p152 

    Objectives: Identification of the most influential scientific publications and directions of mainstream reirradiation research. Methods: A systematic search of the database Scopus (Elsevier B.V., www.scopus.com) was performed, which focused on the time period 1998-2010. Patterns of citation were...

  • Melanoma on upswing despite early detection. Nash, Karen // Dermatology Times;Aug2004, Vol. 25 Issue 8, p60 

    Melanoma is the only early detectable cancer where death rates are rising, but the number of people being screened is staying the same. Multiple randomized controlled trials have failed to demonstrate any statistical significance in overall survival and disease-free survival, whether the surgery...

  • NEW DATA FOR PROGRESSION ON ACTIVE SURVEILLANCE; METASTASES IN CRPC. So, Alan // Oncology Exchange;May2013, Vol. 12 Issue 2, p28 

    The article focuses on the results of two clinical trials on prostate cancer presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held on February 14-16, 2013 in Orlando, Florida. The first study emphasizes the importance of followup care in prostate...

  • Surrogate Efficacy Endpoints in Oncology Trials. Markman, Maurie // Pharmaceutical Medicine - New Zealand;2009, Vol. 23 Issue 5/6, p283 

    There will be little debate with the statement that the single most important goal of anti-neoplastic therapy in the setting of advanced or metastatic disease is to substantially prolong overall survival (or 'cure') from the time of initial diagnosis. As a result, this objective has been...

  • Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Atencio, I. A.; Grace, M.; Bordens, R.; Fritz, M.; Horowitz, J. A.; Hutchins, B.; Indelicato, S.; Jacobs, S.; Kolz, K.; Maneval, D.; Musco, M. L.; Shinoda, J.; Venook, A.; Wen, S.; Warren, R. // Cancer Gene Therapy;Feb2006, Vol. 13 Issue 2, p169 

    The major focus of intrahepatic arterial (IHA) administration of adenoviruses (Ad) has been on safety. Currently, there is little published data on the biological responses to Ad when administered via this route. As part of a Phase I study, we evaluated biological responses to a...

  • Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Sato, Yasufumi // International Journal of Clinical Oncology;Aug2003, Vol. 8 Issue 4, p200 

    Angiogenesis is regulated by the balance of pro-angiogenic factors and angiogenesis inhibitors, and the imbalance of these regulators is the cause of pathological angiogenesis, including tumor angiogenesis. Angiogenesis is required for tumor growth and metastasis, and thus constitutes an...

  • P-0269 THE CAIRO4 STUDY: THE ROLE OF SURGERY OF THE PRIMARY TUMOUR WITH FEW OR ABSENT SYMPTOMS IN PATIENTS WITH SYNCHRONOUS UNRESECTABLE METASTASES OF COLORECTAL CANCER: A RANDOMIZED PHASE III STUDY. Jorine, 't Lam - Boer; Linda, Mol; Cornelis, Verhoef; Ton, de Haan; Cornelis, Punt; Johannes, De Wilt; Miriam, Koopman // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii98 

    No abstract available.

  • A Rescue Strategy for Handling Unevaluable Patients in Simon’s Two Stage Design. Belin, Lisa; Broët, Philippe; De Rycke, Yann // PLoS ONE;9/14/2015, Vol. 10 Issue 9, p1 

    For phase II oncology trials, Simon’s two-stage design is the most commonly used strategy. However, when clinically unevaluable patients occur, the total number of patients included at each stage differs from what was initially planned. Such situations raise concerns about the operating...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics